S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 25 of 25

Issue Date	Title / Author(s) / Citation	File
2014-02	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC Ou, Sai-Hong I.; Jaenne, P. A.; Bartlett, C. H.; Tang, Y.; Kim, D. -W.; Otterson, G. A.; Crino, L.; Selaru, P.; Cohen, D. P.; Clark, J. W.; Riely, G. J. Annals of Oncology, Vol.25 No.2, pp.415-422	DOI
2014-12	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score Lee, Dae-Won; Shin, Dong-Yeop; Kim, Jin Wook; Keam, Bhumsuk; Kim, Tae Min; Kim, Hak Jae; Kim, Dong-Wan; Wu, Hong-Gyun; Paek, Sun Ha; Kim, Young Whan; Heo, Dae Seog; Kim, Dong Gyu; Lee, Se-Hoon Lung Cancer, Vol.86 No.3, pp.363-368	DOI
2014-12	The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer Sim, Sung Hoon; Keam, Bhumsuk; Kim, Dong-Wan; Kim, Tae Min; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog Journal of Cancer Research and Clinical Oncology, Vol.140 No.12, pp.2135-2142	DOI
2015-04	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer Jaenne, Pasi A.; Yang, James Chih-Hsin; Kim, Dong-Wan; Planchard, David; Ohe, Yuichiro; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Su, Wu-Chou; Horn, Leora; Haggstrom, Daniel; Felip, Enriqueta; Kim, Joo-Hang; Frewer, Paul; Cantarini, Mireille; Brown, Kathryn H.; Dickinson, Paul A.; Ghiorghiu, Serban; Ranson, Malcolm New England Journal of Medicine, Vol.372 No.18, pp.1689-1699	DOI
2015-05	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) Blumenschein, G. R., Jr.; Smit, E. F.; Planchard, D.; Kim, D. -W.; Cadranel, J.; De Pas, T.; Dunphy, F.; Udud, K.; Ahn, M. -J.; Hanna, N. H.; Kim, J. -H.; Mazieres, J.; Kim, S. -W.; Baas, P.; Rappold, E.; Redhu, S.; Puski, A.; Wu, F. S.; Jaenne, P. A. Annals of Oncology, Vol.26 No.5, pp.894-901	DOI
2016-03	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D. Annals of Oncology, Vol.27 No.3, pp.417-423	DOI
2016-04	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S. W.; Felip, Enriqueta; Chow, Laura Q. M.; Camidge, D. Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J.; Solomon, Benjamin J.; Wolf, Juergen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Sutradhar, Santosh; Li, Siyu; Szczudlo, Tomasz; Yovine, Alejandro; Shaw, Alice T. The Lancet Oncology, Vol.17 No.4, pp.452-463	DOI
2016-05	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Park, Keunchil; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kolbeck, Arvis Karl; Laurie, Scott A.; Tsai, Chun-Ming; Shahidi, Mehdi; Kim, Miyoung; Massey, Dan; Zazulina, Victoria; Paz-Ares, Luis The Lancet Oncology, Vol.17 No.5, pp.577-589	DOI
2017-02	Regulation of voltage-gated potassium channels attenuates resistance of side-population cells to gefitinib in the human lung cancer cell line NCI-H460 Choi, Seon Young; Kim, Hang-Rae; Ryu, Pan Dong; Lee, So Yeong BMC pharmacology & toxicology, Vol.18, p. 14	DOI
2017-04	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component Yang, James Chih-Hsin; Ahn, Myung-Ju; Kim, Dong-Wan; Ramalingam, Suresh S.; Sequist, Lecia V.; Su, Wu-Chou; Kim, Sang-We; Kim, Joo-Hang; Planchard, David; Felip, Enriqueta; Blackhall, Fiona; Haggstrom, Daniel; Yoh, Kiyotaka; Novello, Silvia; Gold, Kathryn; Hirashima, Tomonori; Lin, Chia-Chi; Mann, Helen; Cantarini, Mireille; Ghiorghiu, Serban; Janne, Pasi A. Journal of Clinical Oncology, Vol.35 No.12, pp.1288-1296	DOI
2017-05	Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy Lim, Yu Jin; Chang, Ji Hyun; Kim, Hak-Jae; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Paeng, Jin Chul; Kang, Keon Wook; Chung, June-Key; Jeon, Yoon Kyung; Chung, Doo Hyun; Wu, Hong-Gyun Clinical Lung Cancer, Vol.18 No.3, pp.e169-e178	DOI
2017-05	Molecular Testing of Lung Cancers Shim, Hyo Sup; Choi, Yoon-La; Kim, Lucia; Chang, Sunhee; Kim, Wan-Seop; Roh, Mee Sook; Kim, Tae-Jung; Ha, Seung Yeon; Chung, Jin-Haeng; Jang, Se Jin; Lee, Geon Kook Journal of Pathology and Translational Medicine, Vol.51 No.3, pp.242-254	DOI
2017-08	Scientific Advances in Thoracic Oncology 2016 Soo, Ross A.; Stone, Emily C. A.; Cummings, K. Michael; Jett, James R.; Field, John K.; Groen, Harry J. M.; Mulshine, James L.; Yatabe, Yasushi; Bubendorf, Lukas; Dacic, Sanja; Rami-Porta, Ramon; Detterbeck, Frank C.; Lim, Eric; Asamura, Hisao; Donington, Jessica; Wakelee, Heather A.; Wu, Yi-Long; Higgins, Kristin; Senan, Suresh; Solomon, Benjamin; Kim, Dong-Wan; Johnson, Melissa; Yang, James C. H.; Sequist, Lecia V.; Shaw, Alice T.; Ahn, Myung-Ju; Costa, Daniel B.; Patel, Jyoti D.; Horn, Leora; Gettinger, Scott; Peters, Solange; Wynes, Murry W.; Faivre-Finn, Corinne; Rudin, Charles M.; Tsao, Anne; Baas, Paul; Kelly, Ronan J.; Leighl, Natasha B.; Scagliotti, Giorgio V.; Gandara, David R.; Hirsch, Fred R.; Spigel, David R. Journal of Thoracic Oncology, Vol.12 No.8, pp.1183-1209	DOI
2018-02	Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection Kim, Hyungjin; Chae, Kum Ju; Yoon, Soon Ho; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Goo, Jin Mo; Park, Chang Min European Radiology, Vol.28 No.2, pp.861-868	DOI
2018-03	Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer Ramalingam, Suresh S.; Yang, James C. -H.; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Mann, Helen; Rukazenkov, Yuri; Ghiorghiu, Serban; Stetson, Daniel; Markovets, Aleksandra; Barrett, J. Carl; Thress, Kenneth S.; Janne, Pasi A. Journal of Clinical Oncology, Vol.36 No.9, pp.841-849	DOI
2018-11	Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer Wu, Yi-Long; Zhang, Li; Kim, Dong-Wan; Liu, Xiaoqing; Lee, Dae Ho; Yang, James Chih-Hsin; Ahn, Myung-Ju; Vansteenkiste, Johan F.; Su, Wu-Chou; Felip, Enriqueta; Chia, Vincent; Glaser, Sabine; Pultar, Philippe; Zhao, Sylvia; Peng, Bin; Akimov, Mikhail; Tan, Daniel S. W. Journal of Clinical Oncology, Vol.36 No.31, pp.3101-3109	DOI
2019-07	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer Choi, Mihong; Keam, Bhumsuk; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Clinical Lung Cancer, Vol.20 No.4, pp.E442-E451	DOI
2020-03	Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis Cho, Byoung Chul; Kim, Dong-Wan; Park, Keunchil; Lee, Jong-Seok; Yoo, Seung Soo; Kang, Jin Hyoung; Lee, Sung Yong; Kim, Cheol Hyeon; Jang, Seung Hun; Kim, Young-Chul; Yoon, Hyoung-Kyu; Han, Ji-Youn; Kim, Sang-We Current Medical Research and Opinion, Vol.36 No.3, pp.477-482	DOI
2020-03	Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia Shin, Hyejin; Choi, Soo Young; Kee, Kyung-Mi; Kim, Soo-Hyun; Yang, Seon-Young; Jung, Su Young; Noh, Hayeon; Zang, Dae Young; Kim, Dong-Wook; Lee, Jang Ik International Journal of Hematology, Vol.111 No.3, pp.417-426	DOI
2020-11	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial Wu, Yi-Long; Cheng, Ying; Zhou, Jianying; Lu, Shun; Zhang, Yiping; Zhao, Jun; Kim, Dong-Wan; Soo, Ross Andrew; Kim, Sang-We; Pan, Hongming; Chen, Yuh-Min; Chian, Chih-Feng; Liu, Xiaoqing; Tan, Daniel Shao Weng; Bruns, Rolf; Straub, Josef; Johne, Andreas; Scheele, Jurgen; Park, Keunchil; Yang, James Chih-Hsin The Lancet Respiratory Medicine, Vol.8 No.11, pp.1132-1143	DOI
2021-06	Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia Shin, Hyejin; Ha, Jung-Eun; Zang, Dae Young; Kim, Sung-Hyun; Do, Young Rok; Lee, Won Sik; Kim, Dong-Wook; Lee, Jangik, I Clinical Lymphoma Myeloma & Leukemia, Vol.21 No.6, pp.E521-E529	DOI
2022-01	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer Janne, Pasi A.; Baik, Christina; Su, Wu-Chou; Johnson, Melissa L.; Hayashi, Hidetoshi; Nishio, Makoto; Kim, Dong-Wan; Koczywas, Marianna; Gold, Kathryn A.; Steuer, Conor E.; Murakami, Haruyasu; Yang, James Chih-Hsin; Kim, Sang-We; Vigliotti, Michele; Shi, Rong; Qi, Zhenhao; Qiu, Yang; Zhao, Lihui; Sternberg, David; Yu, Channing; Yu, Helena A. Cancer Discovery, Vol.12 No.1, pp.74-89	DOI
2022-06	ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges Chow, Laura Q. M.; Barlesi, Fabrice; Bertino, Erin M.; van den Bent, Martin J.; Wakelee, Heather A.; Wen, Patrick Y.; Chiu, Chao-Hua; Orlov, Sergey; Chiari, Rita; Majem, Margarita; McKeage, Mark; Yu, Chong-Jen; Garrido, Pilar; Hurtado, Felipe K.; Arratia, Pilar Cazorla; Song, Yuanbo; Branle, Fabrice; Shi, Michael; Kim, Dong-Wan Clinical Cancer Research, Vol.28 No.12, pp.2506-2516	DOI
2022-10	Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia Kim, Eunjung; Hwang, Eo-Jin; Lee, Junghye; Kim, Dae-Young; Kim, Jae-Young; Kim, Dong-Wook NEOPLASIA, Vol.32	DOI
2023-10	Amivantamab plus lazertinib in osimertinib-relapsed <i>EGFR</i>-mutant advanced non-small cell lung cancer: a phase 1 trial Cho, Byoung Chul; Kim, Dong-Wan; Spira, Alexander I.; Gomez, Jorge E.; Haura, Eric B.; Kim, Sang-We; Sanborn, Rachel E.; Cho, Eun Kyung; Lee, Ki Hyeong; Minchom, Anna; Lee, Jong-Seok; Han, Ji-Youn; Nagasaka, Misako; Sabari, Joshua K.; Ou, Sai-Hong Ignatius; Lorenzini, Patricia; Bauml, Joshua M.; Curtin, Joshua C.; Roshak, Amy; Gao, Grace; Xie, John; Thayu, Meena; Knoblauch, Roland E.; Park, Keunchil Nature Medicine, Vol.29 No.10, pp.2577-2585	DOI